Rights issue in BergenBio ASA (NO) — NOK 250 million

Carnegie acted as joint manager in the fully covered rights issue of NOK 250 million, of which NOK 175 million is underwritten. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.